Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERATE: QEL-001 in liver transplant recipients
NCT05234190Phase 2Active, not recruiting
- Sponsor
- Quell Therapeutics
- Start
- Jan 2022
- Primary completion
- Feb 2026
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of QEL-001 in Liver transplant rejection, sponsored by Quell Therapeutics. Primary endpoints: Safety and Tolerability at 28 days and Long-term safety at 15 years. Started Jan 2022; status: active, not recruiting.
02
Drugs
QEL-001
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT05234190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234190.